Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo, Cancer Res, vol.18, pp.7283-92, 2008. ,
,
Curcumin (diferuloylmethane) inhibits constitutive NF-kap-paB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma, Biochem Pharmacol, vol.5, pp.700-713, 2005. ,
,
Nuclear factor-kB and STAT3 are constitutively active in CD138 C cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis, Blood, vol.103, pp.3175-84, 2004. ,
,
Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human myeloma cells, J Immunol, vol.171, pp.3863-71, 2003. ,
,
Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells, Mol Oncol, vol.2, pp.317-343, 2008. ,
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and botezomib against human multiple myeloma in nude mice model, Mol Cancer Ther, vol.8, pp.959-70, 2009. ,
,
The molecular classification of multiple myeloma, Blood, vol.108, pp.2020-2048, 2006. ,
Molecular pathogenesis of multiple myeloma: basic and clinical updates, Int J Hematol, vol.97, pp.313-336, 2013. ,
The use of molecular-base risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma, Int J Hematol, vol.94, pp.321-354, 2011. ,
,
Mcl -1 is overexpressed in multiple myeloma and associated with relapse and shorter survival, Leukemia, vol.9, pp.1248-52, 2005. ,
Emerging Bcl -2 inhibitors for the treatment of cancer, Expert Opin Emerg Drugs, vol.1, pp.59-70, 2011. ,
,
Cell Death via DR5, but not DR4, is regulated by p53 in myeloma cells, Cancer Res, vol.17, pp.4562-73, 2012. ,
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells, Br J Haematol, vol.100, pp.637-683, 1998. ,
,
Antisense strategy shows that Mcl -1 rather than Bcl -2 or Bcl -x(L) is an essential survival protein of human myeloma cells, Blood, vol.100, pp.194-99, 2002. ,
ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, pp.3901-3911, 2011. ,
Apoptotic machinery diversity in multiple myeloma molecular subtypes ,
, Front Immunol, vol.4, pp.1-6, 2013.
Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other, Leuk Lymphoma, 2014. ,
Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies, J Clin Oncol, vol.9, pp.1898-1904, 2011. ,
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma, Haematologica, vol.95, pp.1973-76, 2010. ,
Curcumin induces apoptosis in human melanoma cells through a Fas/receptor/caspase-8 pathway independent of p53, Exp Cell Res, vol.2, pp.305-319, 2001. ,
Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo controlled crossover 4g study and an open-label 8g extension study, Am J Hematol, vol.5, pp.455-60, 2012. ,
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines, Haematologica, vol.4, pp.574-82, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00550232
Noxa up-regulation and Mcl -1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma, Cancer Res, vol.67, pp.5418-5442, 2007. ,
,